UniversitÈ Laval

Jenny Roy

René Maltais

Donald Poirier

The present application discloses 17&#x3b2; hydroxy steroid dehydrogenase (17&#x3b2; HSD) type 1, 3, 10 inhibitors and use thereof (alone and in combination) in the treatment of cancer and other afflictions. 17&#x3b2; HSD1 inhibitors include estradiol derivatives with a nieta-carbamoylbenzyl substituent at C 16. 17&#x3b2; HSD3/HSD10 inhibitors include androsterone derivatives substituted at the C3 position with a sulfonamide piperazine. Also disclosed are compounds that are inhibitors of both 17&#x3b2; HSD1 and 17&#x3b2; HSD3 that have a spiro-morpholine substituent at C20.

Inhibitors of 17&#x3b2;-HSD1, 17&#x3b2;-HSD3 and 17&#x3b2;-HSD10

Novel chemical agents are described herein. More specifically, 2-(N-substituted piperazinyl) pregnane and 2-(N-substituted piperazinyl) androstane derivatives exhibiting cytotoxicity on a variety of cancer cell lines are disclosed herein.

Growing community of inventors

Saint-Jean-Chrysostome, Canada

Jenny Roy